GlobeNewsWire
05 Nov 2025, 21:05 UTC · 46w ago
Verdict
Headline takes no side. We score ADPT +0.80 across five claims — strongly bullish.
+0.80strongly bullish
More positive than 88% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish
Adaptive Biotechnologies' MRD business has achieved profitability and cash flow positivity.
More positive than 99% of claims this week
The company raised its full-year revenue guidance for the MRD business to a range of $202 million to $207 million.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 93% of claims this week
The Genentech Agreement was terminated in August 2025, contributing $33.7 million in one-time amortization revenue this quarter.
More negative than 85% of claims this week
The company updated its full-year cash burn guidance downward to a range of $45 million to $50 million.
So whatReduced cash burn extends the company's runway and lowers the immediate risk of dilutive financing.
More positive than 66% of claims this week
Excluding the one-time Genentech revenue, the company reported a net loss of $24.2 million for the third quarter.
More negative than 68% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
Reported strong revenue growth, a swing to net income from a loss, and raised full-year revenue guidance for its MRD business.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Proactive Investors
1h ago
+62.1%
Price agrees with the score
$28.51 vs $17.59 close before publication (Nov 5) · not market-adjusted
ADPT chart →
